SCHEMBL2266367

SCHEMBL2266367

COc1cc2c(cc1NS(C)(=O)=O)OC(C)(C)C(=O)N2c1ccc(F)cc1

nearest known ligand 0.67

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 7/20 0.67
LRRK2 Q5S007 2/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
SCN9A Q15858 1/20 0.39
ALDH1A1 P00352 3/20 0.39
BRD4 O60885 1/20 0.38
HSD11B1 P28845 1/20 0.36
PIK3CD O00329 2/20 0.36
PIK3R1 P27986 2/20 0.36
MTOR P42345 2/20 0.36
NR3C1 P04150 1/20 0.36
PGR P06401 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
PIK3CB P42338 1/20 0.34
PIK3CG P48736 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL754239 0.86 NR3C2 (0.71) NR3C2BRD4PIK3CDPIK3R1MTOR
SCHEMBL761147 0.85 NR3C2 (0.70) NR3C2BRD4PIK3CDPIK3R1MTOR
SCHEMBL755350 0.85 NR3C2 (0.70) NR3C2SCN9ABRD4PIK3CDPIK3R1
SCHEMBL755189 0.85 NR3C2 (0.70) NR3C2LRRK2BRD4PIK3CDPIK3R1
SCHEMBL4530965 0.82 NR3C2 (0.65) NR3C2MEN1KMT2ASCN9AALDH1A1
SCHEMBL5088338 0.81 NR3C2 (0.67) NR3C2ALDH1A1BRD4PIK3CDPIK3R1
Mt-3995 SCHEMBL753911 0.81 NR3C2 (1.00) NR3C2BRD4
SCHEMBL755856 0.81 NR3C2 (0.54) NR3C2LRRK2MEN1KMT2ASCN9A
SCHEMBL754758 0.80 NR3C2 (0.67) NR3C2MEN1KMT2ASCN9ABRD4
SCHEMBL4979414 0.78 NR3C2 (0.71) NR3C2SCN9ABRD4PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188073-B2 Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
US-20110251185-A1 BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS IIJIMA TORU 2011-10-13 US disclosed
US-7998956-B2 Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-08-16 US disclosed
US-20090023716-A1 Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-01-22 US disclosed
EP-1984345-A1 BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS Mitsubishi Tanabe Pharma Corporation (JP) 2008-10-29 EP disclosed
WO-2007089034-A1 BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023716-A1 Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents NR3C2, MC2R, NR3C1 NR3C2 1/4885LRRK2 3961/4885MEN1 1447/4885
US-20110251185-A1 BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS NR3C2, MC2R, NR3C1 NR3C2 1/4885LRRK2 3961/4885MEN1 1447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.